Posts Tagged ‘neurotechnologies’
Integrating music, movement and stroke rehabilitation, MedRhythms raises $25M to develop and commercialize digital therapeutic
MedRhythms raises 25m to get patients back in tune after a stroke (TechCrunch): MedRhythms secured $25 million in Series B funding to advance its digital therapy platform aimed at measuring and improving someone’s ability to walk after they have experienced a neurologic injury or disease … Company co-founder and CEO Brian Harris was a neurologic music…
Read MoreUpdate on the aducanumab (Aduhelm) saga, retirement, financial advice, cognitive health, excessive worrying, neurotech, and more
Welcome to a new edition of SharpBrains’ e‑newsletter, providing this time a summary of the saga around the FDA approval of aducanumab (Aduhelm) as a supposed treatment for Alzheimer’s Disease, plus a range of timely research findings and resources for lifelong brain health. First, below are some key reads to navigate “probably the worst drug approval…
Read MoreEye-tracking pioneer Smart Eye acquires MIT spin-off Affectiva to augment driver monitoring systems and more
Emotion-detection software start-up Affectiva acquired for $73.5M (TechCrunch): Smart Eye, the publicly traded Swedish company that supplies driver monitoring systems for a dozen automakers, has acquired emotion-detection software startup Affectiva for $73.5 million in a cash-and-stock deal.
Read MoreOn building better brains at any age, treating Depression vs. Dementia, emerging neurotechnologies, psychedelics, and more
Welcome to a new edition of SharpBrains’ e‑newsletter, featuring eleven new research findings and innovative resources for lifelong cognitive and brain health. #1. Debate: Are depression and dementia two sides of the same coin? And, if they are, how to best approach treatment? #2. Either way, the earlier the better, but it’s never too late: New…
Read MoreReading Our Minds: New book issues strong call to action to modernize psychiatry
The Rise of Big Data Psychiatry (The Wall Street Journal): As a physician, I need to figure out three things when a new patient walks into my office: what their life is typically like, what has changed that made them seek treatment and what I can do to help them. It’s a complex problem, and…
Read MoreClick Therapeutics raises $30 million in debt to advance commercialization of smoking cessation app Clickotine
Click Therapeutics Secures $30M in Growth Capital from K2 HealthVentures to Expand Operations (press release): Click Therapeutics, Inc. (“Click”), a leader in Digital Therapeutics™ solutions as prescription medical treatments, today announced $30 million in debt financing from K2 HealthVentures (K2HV), a healthcare-focused specialty finance company, to accelerate commercialization of its leading smoking cessation solution, Clickotine™,…
Read More